Trial Profile
Efficacy and safety of oral budesonide in the prevention of acute gastrointestinal graft-versus-host disease [GVHD] following allegeneic stem cell transplantation [SCT].
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms PROGAST
- 10 May 2011 Results presented at the Digestive Disease Week 2011.
- 06 Apr 2010 Actual end date added to 1 Aug 2005 as reported by ClinicalTrials.gov.
- 06 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.